Tag: Nativa

Nativa is Russian pharmaceutical company specializing in the research, development and manufacturing of finished drugs.

Nativa operates in line with Federal Targeted Program Development of the Pharmaceutical Industry in the Russian Federation in the Period Until 2020 and Beyond. The company is an active participant in the government’s import substitution program for public procurement of pharmaceutical products. Nativa has its own research and development facilities with the full process cycle in place, from pharmaceutical fine chemicals to finished dosage forms.

The company’s production facilities are located in Krasnogorsky district of Moscow region. An agreement has also been reached to cooperate with manufacturing sites in Ufa and Kursk. Our pharmaceutical production complies with the European Union Good Manufacturing Practice (GMP).

The company’s strategic focus is on the development and launch of pulmonary drugs on the Russian market.

The company’s plans involve an expanded range of the most popular drugs, including vital and essential medicines not manufactured domestically and not protected by foreign patents in the Russian Federation. The company works closely with pioneering developers of complex process solutions and implements partner programs to share unique international experience and transfer innovative pharmaceutical technology to Russia.

Nativa offers a wide range of high-technology medicinal products for effective,high-quality and affordable treatment. Our products are available in all regions of the Russian Federation.

Nativa Won Several Legal Disputes over Pfizer

The issuing of a compulsory license for the production of a patent-protected drug in Russia may take place shortly, due to the recent victory of several legal disputes with US pharma giant Pfizer by l...

Nativa won a patent dispute with Bristol-Myers Squibb with regard to dasatinib

The Arbitration Court of the Moscow region decided to fully reject the claims filed by Bristol-Myers Squibb Holdings Ireland against Nativa LLC under the case No. A41-87845/2017.

Nativa received a license to use dependent invention

On June 1, 2018, the Moscow Arbitration Court satisfied the claim to issue a license for the use of a Celgene’s patent in respect of dependent invention, which Nativa LLC plans to use in the manufacturing of medicinal product.

Nativa won in court its patent dispute with Bayer

The Arbitration Court of Moscow region decided to reject the claim of Bayer (Bayer Healthcare LLC) to Nativa, a Russian company, aimed at recognizing and stopping the actions that violate the exclusive rights of the plaintiff.

Nativa signs agreements on supplying its products to several countries

At the Arab Health 2018, the largest exhibition of the Middle East in the area of medicine and health, the management of Nativa signed a number of agreements on supplying the products to the Middle East and East Asia

Nativa starts manufacturing multi-dose powder inhalers

In 2018 Nativa will launch the manufacturing of multi-dose powder inhalers for the treatment of bronchopulmonary diseases

Nativa develops its pulmonology drug area

For several years, Nativa, a pharmaceutical company, has been intensively developing a production line for pulmonology drugs. “This year, we set a strategic goal to capture the half of this segment...

Pharmaceuticals requiring complex synthesis set a promising niche in Russia

It seems like pharmaceutical Russia has already found its niche, at least the most promising national manufacturers get concentrated on development and marketing of highly-tailored medicinal drugs int...